Attachment
Gates Package, p.245 · gates:exh:00138
Page text: p.245 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
Members of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Partnership
Bill & Melinda Gates Foundation
Emilio Emini, Ph.D.
Director, TB & HIV Program
Bill & Melinda Gates Foundation
Emily Erbelding, M.D., M.P.H.
Director, Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases, NIH
Stan Erck, M.B.A.
President and Chief Executive Officer
Novavax
Anthony Fauci, M.D.
Director, National Institute of Allergy and Infectious Diseases
NIH
Gary Gibbons, M.D.
Director, National Heart, Lung, and Blood Institute
NIH
Penny Heaton, Ph.D.
Chief Executive Officer
Bill & Melinda Gates Medical Research Institute
Tom Hudson, M.D.
Senior Vice President, R&D; Chief Scientific Officer
AbbVie
Eric Hughes, M.D., Ph.D.
Global Development Unit Head, Immunology, Hepatology & Dermatology and China Region
Development Head
Novartis
Kathrin Jansen, Ph.D.
Senior Vice President and Head of Vaccine Research and Development
Pfizer
Robert Johnson, PhD.
Director, Division of Influenza and Emerging Infectious Diseases
Biomedical Advanced Research and Development Authority
Lynn Kramer, M.D.
Vice President, Chief Clinical Officer, Neurology Business Group
Eisai
Michael Kurilla, M.D., Ph.D.